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Summary 
Multiple sclerosis is a major cause of neurologic disability, which accrues predominantly during 
progressive forms of the disease. While development of multifocal inflammatory lesions is the 
underlying pathologic process in relapsing-remitting multiple sclerosis, the gradual accumulation 
of disability that characterizes progressive multiple sclerosis appears to result from more diffuse 
immune mechanisms and neurodegeneration. As a result, the13 anti-inflammatory medications 
with regulatory approval to treat relapsing-remitting multiple sclerosis have little or no efficacy in 
progressive multiple sclerosis without inflammatory lesion activity. Thus, effective therapies for 
progressive multiple sclerosis that prevent worsening, reverse damage, and restore function 
represent major unmet needs. This review summarizes the current status of therapy for 
progressive multiple sclerosis and outlines prospects for the future. 
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Introduction 
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system. 
The global prevalence of MS was estimated at 2·3 million in 2013,1 an increase of 0·2 million 
from five years earlier. This prevalence is likely an underestimate and does not fully account for 
the number of patients with MS in large Asian countries. Approximately 15% of patients begin 
with a progressive disease course from onset, termed primary progressive MS (PPMS); 
approximately 70% develop progression 10–15 years after an initial relapsing-remitting (RR) 
course, termed secondary progressive MS (SPMS). Thus, at least 1·3 million people have 
progressive MS. 
Disability in MS accrues predominantly in the progressive forms of the disease, creating a 
significant healthcare burden at the individual, family, and community levels. Although 
substantial progress has been made in the treatment of RRMS – 13 medications currently have 
regulatory approval – development of therapies that prevent or reverse progression has been 
slower. International efforts such as the International Progressive MS Alliance are increasing the 
focus on PMS and identifying specific research areas to target.2 This review summarizes the 
current status of therapy for progressive MS and outlines prospects for the future. 
 
Current understanding of the pathogenesis of progressive multiple sclerosis 
The pathogenic mechanisms underlying progression are incompletely understood. Moreover, 
since the division 25 years ago of what previously was called chronic progressive MS into 
PPMS and SPMS, it remains uncertain whether they represent overlapping or distinct entities.3 
Patients with PPMS and SPMS both exhibit gradually worsening disability, most often motor 
impairment with a pattern suggesting a myelopathy but also may have progressive hemiparesis, 
ataxia, visual dysfunction, or cognitive impairment. While the onset of progression commonly 
occurs at age 40-50 in both groups, SPMS follows an initial RR phase typically lasting 10–15 
years. Patients with PPMS have an equal gender balance, while SPMS more commonly affects 
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women. In patients with radiologically isolated syndrome (MRI findings typical of MS without 
clinical manifestations), a small proportion have clinical conversion manifested as gradual 
progression of disability.4 The proportion, demographics, gender balance, clinical 
characteristics, and frequency of cord lesions are similar to those of PPMS in the overall MS 
population. The current consensus is that PPMS is biologically part of the MS spectrum, and the 
clinical, imaging, and pathological differences between PPMS and SPMS are more relative than 
absolute. Therefore, in much of this review, PPMS and SPMS will be discussed together as 
progressive MS (PMS). 
The pathological mechanisms causing tissue damage in RRMS and PMS overlap but differ 
quantitatively. In the early stages, MS pathology is dominated by focal inflammatory lesions with 
perivenular accumulation of T and B lymphocytes, blood-brain barrier disruption, demyelination, 
and acute axonal transection.5 Although focal lesions sometimes develop in PMS, new lesion 
activity becomes less frequent over time. In contrast, diffuse pathology in grossly normal-
appearing white and gray matter with microglial activation and neurodegeneration are more 
prominent.6 These features are found in early MS as well, but increase with age and disease 
duration. 
The clinical importance of gray matter pathology involving cortex, deep structures, 
cerebellum, and spinal cord in PMS is increasingly recognized.7 Several types of cortical lesions 
have been distinguished: leukocortical (subcortical lesions affecting adjacent white and gray 
matter), intracortical, and subpial lesions (spanning long distances in the subpial ribbon and 
extending from the surface to cortical layers II or IV).8 Cortical histopathology includes microglial 
activation, demyelination, neuritic transection, neuronal death, and reduced presynaptic 
terminals but tends not to include perivascular lymphocytic cuffs typical of white matter lesions.8 
Subpial lesions may be associated with meningeal infiltrates of T and B lymphocytes, plasma 
cells, and macrophages,6 which in some cases of SPMS form structures resembling lymphoid 
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follicles.9 The severity of cortical demyelination correlates with the extent of meningeal 
inflammation in PMS, suggesting a pathogenic role.10 
A number of potential mechanisms are hypothesized to lead to neurodegeneration in PMS 
(Figure 1),11 many of which are potential therapeutic targets. Demyelinated axons are abundant 
in longstanding MS and are hypothesized to be susceptible to chronic injury.6 In addition to loss 
of myelin’s structural and trophic support, chronic demyelination might permit increased 
exposure to toxic species in the microenvironment: inflammatory mediators, and reactive 
oxygen and iron species. In some demyelinated axons, saltatory nerve impulse conduction is 
replaced by continuous conduction, which restores function but increases energy demand and 
sodium accumulation in the axonal cytoplasm. Resultant reverse operation of sodium-calcium 
exchanger to restore ionic gradients could lead to cytoplasmic calcium accumulation, activation 
of calpains, and proteolysis of cytoskeleton. As discussed below, studies of sodium channel 
blockers had mixed results.12,13 Although remyelination can be seen in some lesions, the failure 
of remyelination in other areas is hypothesized to cause axonal degeneration and disease 
progression. Thus, remyelination is a potential therapeutic goal. The abundance of 
oligodendrocyte precursors in some chronic lesions suggests that lack of such cells does not 
explain failure of remyelination.14 Rather, the absence of factors necessary for successful 
remyelination or the presence of inhibitory factors is more likely responsible. This concept has 
important implications for potential repair-promoting strategies. 
Axonal injury also is a major contributor to irreversible disability. This injury is believed to 
occur through a combination of acute inflammatory damage, degeneration of chronically 
demyelinated axons in white and gray matter, and antegrade and retrograde trans-synaptic 
degeneration due to distal axonal transection.15 There is increasing evidence that mitochondrial 
dysfunction in axons results from impaired mitochondrial transport, susceptibility to oxidative 
injury, and mutations in mitochondrial DNA, all of which lead to impaired energy production and 
generation of reactive oxygen species. The net effect of these processes is accumulation of 
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various toxic species, increased cellular energy demand, failure of energy production, and 
virtual hypoxia resulting in neurodegeneration. Improved energy production is the proposed 
mechanism of action of high-dose biotin.16 
 
Revised multiple sclerosis phenotype classification 
Increasing recognition that relapses and MRI lesion activity occur in some patients with PMS, 
mainly in the early stages, led to recent revision of the phenotypic categories of PMS (Figure 
2).17 The new scheme still differentiates progression at disease onset (PPMS) from progression 
after an initial RR course (SPMS) but adds two qualifiers: presence or absence of clinical 
relapses or new MRI lesions (“active” or “not active”), and presence or absence of gradual 
worsening disability independent of relapses (“with progression” or “without progression”). 
These qualifiers are intended to be re-assessed over time, e.g. annually, with patients 
potentially changing category based on recent disease course. 
The new classification will have significant benefits in recognizing two relatively separate 
facets of PMS – inflammatory lesion activity and gradual progression. The classification will be 
especially helpful for selection of informative clinical trial participants. As discussed below, the 
presence of recent relapses or active MRI lesions is an important determinant of efficacy in 
PMS of medications with predominantly anti-inflammatory effects. It is hoped that in the future, 
phenotypic classification will incorporate additional imaging and non-imaging biomarkers, 
genetic markers, and epigenetic factors to categorize patients more comprehensively. 
 
Clinical measures of disability 
Clinical outcome measures must take into account heterogeneous clinical manifestations, 
unpredictable course, and generally slow rate of worsening in PMS. The current measures 
address these issues in different ways.18 The Kurtzke Expanded Disability Status Scale (EDSS) 
is based on the neurologic examination and assesses a range of neurological functions, 
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permitting comparison between individuals or groups on a 0–10 scale. Despite limitations, the 
EDSS is likely to continue to be used as a measure of MS-related disability. An alternative 
approach, the MS Functional Composite (MSFC), uses quantitative neuroperformance tests 
covering four neurologic domains – Timed 25-Foot Walk (T25FW, short-distance walking 
speed), Nine-Hole Peg Test (9HPT, upper extremity function), Sloan low contrast letter acuity 
(vision), and Paced Auditory Serial Addition Test or Symbol Digit Modalities Test (cognitive 
processing speed and sustained attention). Anticipated advantages of the MSFC compared to 
the EDSS are ease of administration, more meaningful contribution from several neurologic 
domains, improved reliability, and greater sensitivity in some populations. The Multiple Sclerosis 
Outcome Assessments Consortium comprising MS clinical researchers from academia and 
industry currently is working to develop the MSFC approach further and obtain formal regulatory 
qualification for use in MS trials.19 The INFORMS trial of fingolimod in PPMS20 employed a 
composite outcome measure combining EDSS, T25FW, and 9HPT. Although the trial did not 
demonstrate efficacy, the composite endpoint detected events in 69% of participants, more than 
its components. 
A number of automated measurement devices to capture function in MS are under 
development. The MS Performance Test is a battery of quantitative neuroperformance 
assessments modeled after the MSFC designed for supervised or self administration using a 
suite of iPad® apps.21 Several smartphone and wearable motion sensors have been developed, 
which provide the ability to measure community-based ambulation and physical activity. How 
such data can be used to assess therapies in clinical trials or to make therapeutic decisions in 
practice is unclear at present. Nevertheless, it is expected that MS disability assessment will 
undergo further refinement to include various performance measures. Methods for capturing 
large segments of data using the electronic medical record also will expand in the future. 
 
The role of imaging in progressive multiple sclerosis 
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MRI is a key diagnostic tool in all forms of MS. In addition, because of the greater sensitivity of 
MRI compared to clinical outcomes, a standard approach in the development of anti-
inflammatory therapies for RRMS employs MRI lesion activity in phase 2 trials to predict benefit 
on relapses in subsequent phase 3 trials.22 Such a marker is lacking in PMS where lesion 
activity is less common than in RRMS and disability often worsens without lesion accrual. 
Moreover, due to its limited pathologic specificity, standard MRI does not appear to detect the 
pathologic processes that underlie disability progression. Several imaging approaches under 
development show promise to meet this need. 
 
Brain volume measures 
Whole brain atrophy, which reflects aggregate tissue injury, is more severe in PMS compared to 
RRMS, though the rate of volume loss is relatively constant over the course of the disease.23 
Whole brain atrophy correlates with physical23 and cognitive24 impairment. Treatment effects on 
brain atrophy predict effects on disability, at least in RRMS.25 Methods for measuring whole 
brain volume are reasonably well established, and published sample size estimates for PMS 
trials based on whole brain atrophy are feasible.26 The main disadvantage as a phase 2 trial 
outcome is the rather slow rate of change, prolonging trial duration. In addition, precise whole 
brain volume measurement is technically challenging and subject to significant biologic 
variability, making it difficult to implement in clinical practice. 
 
Methods to detect gray matter pathology 
Conventional MRI does not detect cortical lesions, an important site of MS injury. Specialized 
sequences like double inversion recovery27 and ultra-high field (7 tesla) MRI28 allow 
identification of some but not all cortical lesions. Because of the insensitivity of current 
techniques to demonstrate cortical pathology directly, some studies have measured cortical 
thickness or volume to quantify pathology indirectly. Cortical atrophy is prominent in PMS29 and 
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correlates with physical30 and cognitive31 impairment. Atrophy of deep gray structures 
(thalamus, caudate, and hippocampus) also occurs in PMS and can be focal (presumably due 
to lesions) or more diffuse (presumably due to damage to afferent or efferent connections).32,33 
Like whole brain atrophy measures, regional atrophy measures require substantial image post-
processing, making them more suitable for research studies than clinical practice.  
 
“Advanced” MRI techniques 
Several MRI techniques may provide improved pathologic specificity and, thus, better 
correlation with clinical disability: diffusion tensor imaging (DTI, which quantifies the three-
dimensional diffusion of water),34 magnetization transfer imaging (MTI, which quantifies tissue 
integrity through the interaction of protons bound to molecular structures and free water),35 
magnetic resonance spectroscopy (which quantifies tissue metabolites),36 and techniques such 
as magnetic resonance fingerprinting.37 These techniques can be applied to the whole brain, or 
selectively to gray or white matter lesions, or regions that appear normal on standard MRI. All of 
these techniques show promise but require further validation of their pathologic specificity. 
 
Spinal cord imaging 
Spinal cord atrophy correlates with clinical measures of disability.38 Quantitative and more 
pathologically specific MRI measures of spinal cord are difficult due to low spatial resolution, 
pulsation artifact, cerebrospinal fluid partial volume averaging, and challenges in registration. 
Nevertheless, assessment of the spinal cord using DTI,39 MTR,40 and spectroscopy41 may 
provide important insights in PMS. 
 
Positron emission tomography 
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Positron emission tomography markers for activated microglia42 and myelin43 have been 
developed that potentially could assess disease status in PMS. This technique’s principal 
shortcoming is its limited spatial resolution. 
 
Optical coherence tomography 
Optical coherence tomography is a rapid, non-invasive technique that provides high-resolution 
quantification of the retinal nerve fiber layer (the axons that extend to the optic nerve) and the 
corresponding neuronal cells bodies in the ganglion cell layer. These measures directly reflect 
the axonal integrity of the optic nerves and correlate with overall clinical disability44 and brain 
MRI measures.45 
 
Status of disease therapy for progressive multiple sclerosis 
Anti-inflammatory strategies 
Most medications approved for RRMS have been tested in PMS (Table 1). Interferon-β1 
therapies were evaluated in SPMS shortly after their efficacy was demonstrated in RRMS. 
Although two trials were positive,46,47 several others were negative.48-50 Similarly, a phase 3 trial 
of glatiramer acetate in PPMS was negative.51 Subsequent analysis found that trials enriched 
with participants with recent relapses and MRI lesion activity tended to demonstrate benefit from 
interferon-β1.52 Similar results were observed with other anti-inflammatory therapies in PMS. 
Fingolimod, a sphingosine 1-phosphate (S1P) receptor modulator, reduced relapses, MRI 
lesion activity, and brain volume loss in three phase 3 trials in RRMS.53-55 Fingolimod readily 
enters the brain and has direct effects on several central nervous system cell types mediated by 
S1P receptors, suggesting it might be beneficial in PMS.56 A phase 3 trial of fingolimod in PPMS 
demonstrated reduction in new MRI lesions but not the risk of confirmed disability worsening 
measured by a composite outcome that included EDSS, T25FW, and 9HPT.20 These results 
 Page 11 
indicate that entry of a medication into the central nervous system and direct actions there do 
not ensure efficacy in PMS. 
Another highly effective anti-inflammatory therapy, the anti-1 integrin monoclonal antibody 
natalizumab, was evaluated in a phase 3 trial in SPMS. Natalizumab therapy did not slow 
worsening of disability measured by a composite outcome similar to that used to test fingolimod, 
though benefit was seen on 9HPT.57 The lack of benefit on progression of natalizumab, one of 
the more potent anti-inflammatory therapies for RRMS, underscores the importance of 
mechanism of action in determining efficacy. 
Because of the potent efficacy of anti-CD20 monoclonal antibodies in RRMS, there is 
increased recognition of the multifaceted role of B lymphocytes in MS pathogenesis beyond 
antibody production.58 In a phase 3 trial in PPMS, rituximab treatment slowed the change in 
lesion volume relative to placebo, but did not decrease the risk of confirmed disability 
progression.59 In planned subgroup analyses, participants younger than 50 years and those with 
gadolinium-enhancing lesions at baseline showed benefit on disability progression. Based on 
those results, a humanized anti-B lymphocyte monoclonal antibody, ocrelizumab, was evaluated 
in PPMS. This phase 3 trial demonstrated that ocrelizumab reduced the risk of disability 
progression by 24%.60 Importantly, this trial enrolled relatively young participants (mean age 
44.6 years; maximum 55 years), with short disease duration (mean 6.4 years; maximum 15 
years), and a relatively high proportion with gadolinium-enhancing lesions at baseline (26%). 
The subgroup with gadolinium-enhancing lesions at baseline appeared to have a greater 
reduction in risk of disability progression, though the difference was not significant.61 
The different results obtained in PMS trials appear not to relate to differences in anti-
inflammatory potency. Instead, the results suggest that those trials enrolling a study population 
with younger age, shorter disease duration, and more ongoing inflammatory lesion activity tend 
to demonstrate greater benefit. Conversely, older patients without lesion activity gain little if any 
benefit as a group. In addition to study population, mechanism of action also may be relevant, 
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although that requires further study. These observations provide valuable guidance for both the 
characteristics of participants to enroll in future trials and the choice of therapies to study in 
PMS.  
 
Neuroprotective therapeutic strategies 
The limited success of anti-inflammatory agents in treating PMS suggests that other therapeutic 
approaches, such as neuroprotective or repair-promoting strategies, will be necessary. A phase 
2 study assessed the potential cytoprotective properties of simvastatin in SPMS.62 Simvastatin 
produced a 43% reduction in whole brain volume loss and a slowing in disability worsening 
measured by EDSS (absolute difference in means of 0.25 points). Another trial utilized a 
repurposed sodium-channel blocker, phenytoin, to protect axons from acute inflammatory injury 
in acute optic neuritis.12 Phenytoin treatment within two weeks of onset led to a 30% decrease in 
loss of retinal nerve fiber layer thickness relative to placebo. This success is in contrast to the 
negative results with another sodium channel blocker, lamotrigine, in slowing brain volume loss 
in SPMS.13 This discrepancy may relate to a “pseudo-atrophy” effect seen in the first year of the 
lamotrigine study, which may have obscured a potential benefit. Similarly, the neuroprotective 
effects of cannabinoids observed in the laboratory were not confirmed in a trial of the synthetic 
cannabinoid, dronabinol in PPMS and SPMS. Treatment did not reduce disability worsening 
over three years.63 The low progression rate in the placebo group decreased the ability of this 
study to demonstrate benefit. 
Cellular energy metabolism appears to be abnormal in PMS11 and is another potential 
therapeutic target. The vitamin biotin is a coenzyme for many essential carboxylases and, in 
high doses, is hypothesized to enhance cellular energy production with resultant improved 
axonal function, decreased neurodegeneration, and enhanced remyelination.64 A placebo-
controlled phase 3 trial evaluated whether high dose biotin (300 mg/day) improved disability in 
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SPMS and PPMS.16 The study found that 13% of treated participants had improvement in 
measures of disability, compared to none in the placebo group. 
 
Repair-promoting strategies 
LINGO-1 is a protein expressed by oligodendrocytes and neurons that inhibits remyelination.65 
Treatment of patients with acute optic neuritis with the LINGO-1-blocking monoclonal antibody 
BIIB033 did not improve recovery of visual evoked potential latency, a measure of optic nerve 
conduction, in the primary analysis but was effective in a post-hoc “per-protocol” analysis.66 
Negative results of a phase 2 trial assessing whether BIIB033 improves disability in RRMS and 
SPMS (clinicaltrials.gov identifier NCT01864148) recently were announced. 
Cell-based repair-promoting strategies have received much attention as a potential 
therapeutic approach in PMS. Oligodendrocyte progenitor cells (OPCs) can be isolated from 
fetal human brain and when injected intracerebrally into hypomyelinating shiverer mice, lead to 
widespread myelination and reversal of the clinical phenotype.67 A phase 1 dose-escalation trial 
to evaluate the feasibility and safety of intracerebral injections of these cells in SPMS currently 
is planned.68 
An intriguing related approach involves using OPCs69 or OPC-like induced pluripotent stem 
cells70 as the basis for high-throughput screening of already available drugs for their ability to 
stimulate remyelination. Molecules identified in the initial screens were further evaluated by 
increasingly stringent in vitro and in vivo testing, identifying the muscarinic antagonist 
benztropine, the antihistamine clemastine, the imidazole antifungal miconazole, and the topical 
steroid clobetasol as potential candidates for further testing. A pilot study of clemastine showed 
improvement on visual evoked potentials in participants with MS-related chronic optic 
neuropathy.71 
Significant work has assessed mesenchymal stem cell (MSC) transplantation as a potential 
repair-promoting strategy in MS.72 MSCs are pluripotent precursor cells that can be isolated 
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from bone marrow, adipose tissue, and numerous other tissues, and culture-expanded to purity. 
They exhibit numerous immunomodulatory, tissue-protective, and repair-promoting properties.72 
Following several preliminary studies in MS showing good safety and tolerability, the ongoing 
MESEMS phase 2 trial (clinicaltrials.gov identifier NCT01854957) should provide more definitive 
evidence concerning safety and efficacy. However, important methodological questions remain, 
including preferred source (bone marrow versus adipose tissue), cell production protocol to 
optimize yield and potency, whether the cells can be cryopreserved or need to be administered 
immediately, best route of administration (intravenous, intrathecal, or intra-arterial), appropriate 
dose and dosing schedule, and whether the cells should be derived from the patient 
(autologous) or someone without MS (allogeneic).72 
 
Future directions 
The largely disappointing results of studies of anti-inflammatory agents in PMS indicate that 
therapeutics that target other mechanisms will be necessary. One obstacle to development of 
such strategies is our incomplete understanding of the pathophysiology of progression. 
Therefore, the range of approaches under investigation remains relatively broad and without a 
clear pattern of success as yet. MS-SMART (clinicaltrials.gov identifier NCT01910259) is 
applying an adaptive trial design to evaluate three putative neuroprotective agents, amiloride, 
riluzole, and fluoxetine. A second significant obstacle is the lack of a validated phase 2 trial 
methodology that reliably predicts success of neuroprotective and repair-promoting strategies in 
phase 3 studies. Two general approaches have been utilized to date: recovery from an acute 
lesion involving an eloquent pathway (e.g. the optic nerve), or an imaging biomarker (e.g. whole 
brain atrophy). The eloquent pathway approach has the advantage of sensitivity, but the 
relevance to PMS of lessening damage or improving recovery from a focal acute inflammatory 
lesion is uncertain. Conversely, assessing whole brain or regional volume loss appears more 
likely to measure preservation of tissue integrity relevant to PMS but may be insufficiently 
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sensitive for a phase 2 trial. In addition to testing the efficacy of ibudilast in PPMS and SPMS, 
the SPRINT-MS trial (clinicaltrials.gov identifier NCT01982942) is evaluating the relative 
sensitivity of whole brain and regional atrophy measures, DTI, MTI, and OCT to detect 
neuroprotection for use in proof-of-concept clinical trials. At the present time, however, the 
population most likely to benefit from neuroprotective or repair-promoting strategies and the 
optimal trial design to demonstrate benefit have yet to be defined. 
 
Restorative and rehabilitation approaches 
Persons with PMS must manage increasing disability from a wide range of complex interacting 
symptoms, with impairments of gait, vision, and cognition considered the most relevant for those 
who have lived with MS for over 15 years.73 Given the paucity of pharmacologic treatments for 
these symptoms, restorative and rehabilitation approaches form the mainstay of their 
management; highlighted as a key priority by the International Progressive MS Alliance.2 While 
most studies of physiotherapy and multi-disciplinary rehabilitation have focused on RRMS, there 
is some evidence that these approaches are effective in improving ability and participation, and 
importantly health-related quality of life and coping skills in patients with PMS.74 However, a 
recent systematic review found that, while 13 studies showed benefit in at least one outcome 
measure, all either were under-powered or had methodological issues.74 Adequately designed 
clinical trials will be necessary to advance rehabilitation for PMS. 
There is some evidence to suggest that exercise, incorporating endurance or resistance 
training, is feasible in MS,75 and improving physical fitness benefits not only physical but also 
cognitive function.76 Addressing the multiplicity of symptoms in PMS may require a combination 
of approaches and utilise a range of outcomes. A recent pilot trial used three forms of exercise 
and demonstrated benefit in both mobility and cognition.77 Similarly, a recent study showed 
augmented benefit from combining exercise with symptomatic therapy.78 For more disabled 
patients, use of robotics may be helpful.79 Results for gait and balance training have been 
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encouraging, though trial sizes were relatively small. Some benefits also were seen for upper 
limb function weakness and incoordination. 
Numerous studies have demonstrated neuroplasticity in MS, measured with functional 
imaging and, more recently, physiological techniques at the synaptic level.80,81 There is a body 
of evidence suggesting that functional reorganisation following a relapse helps restore function. 
At a cellular level, synaptic plasticity appears to make an important contribution to recovery in 
MS. Long-term potentiation of synaptic transmission may functionally compensate for neuronal 
loss through increasing synaptic excitability of denervated neurons. This phenomenon has been 
demonstrated following relapse but not yet in progression. The challenge will be to incorporate 
approaches that target these mechanisms into active rehabilitation programmes. This issue is 
compounded in PMS by more limited cognitive and motor reserve. 
Finally, management of PMS presents a number of other challenges. This population is older 
with increased likelihood of comorbidities.82 Recognition and treatment of conditions such as 
musculoskeletal disorders, diabetes, cardiac disease, and respiratory dysfunction are necessary 
to maximise levels of ability and participation. In addition, awareness of the factors that lead to 
falls – inevitably associated with increasing disability and therefore more common in PMS – and 
preventative measures to avoid them, is essential.83 
Over and above all of these approaches, embracing a holistic concept of wellness and 
encouraging lifestyle choices across physical, emotional, social, intellectual, occupational, and 
spiritual dimensions is a key element of a comprehensive management plan and one that is 
strongly advocated by people with MS.84 This approach serves to underline the importance of 
self-management at all stages of MS. 
 
Conclusions 
The pathogenic mechanisms underlying acute relapses and progression differ, though both 
processes probably co-exist to varying degrees throughout the course of MS. Therapies 
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approved for RRMS have little or no benefit in PMS in the absence of ongoing inflammatory 
lesion activity. Therapies that prevent progression independent of acute inflammatory pathology 
are needed. Approaches to restore function, both through promoting tissue repair and improving 
function of damaged tissue, also are needed. Successful development of new therapies for 
PMS will require better understanding of the pathogenesis of progression and more sensitive 
clinical and imaging outcome measures. 
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Table: Recent phase 3 clinical trials in progressive multiple sclerosis 
 
Study Population Treatment arms (n) Follow-
up 
duration 
Mean 
age 
(years) 
Proportion 
of 
participants 
with 
gadolinium-
enhancing 
lesions at 
baseline 
Primary 
outcome 
Results 
Anti-inflammatory strategies 
ASCEND57 SPMS natalizumab (439) 
placebo (448) 
96 weeks 47.2 24% 6-month CDW 
based on a 
composite of 
EDSS, 
T25FW, and 
9HPT 
4% increase in 
CDW, 
OR=0.86, 95% 
CI [0.66-1.13], 
p=0.287 
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INFORMS20 PPMS fingolimod (336) 
placebo (487) 
3 years 49 13% 3-month CDW 
based on a 
composite of 
EDSS, 
T25FW, and 
9HPT 
5.05% reduction 
in CDW, 
HR=0.95, 95% 
CI [0.80-1.12], 
p=0.544 
MAESTRO85 SPMS MPB8298 (305) 
placebo (307) 
2 years 49.9 N/A 6-month CDW 
based on 
EDSS 
2.9% increase 
in CDW in 
DR2+/DR4+ 
subgroup, 
p=0.527 
7.5% reduction 
in CDW in DR2-
/DR4- 
subgroup, 
p=0.055 
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OLYMPUS59 PPMS rituximab (292) 
placebo (147) 
96 weeks 49.9 24.5% 3-month CDW 
based on 
EDSS 
8.3% reduction 
in CDW, 
HR=0.77, 95% 
CI [0.55-1.09], 
p=0.144 
ORATORIO60 PPMS ocrelizumab (488) 
placebo (244) 
120 weeks 44.6 
years 
26% 3-month CDW 
based on 
EDSS 
24% reduction 
in CDW, 
HR=0.76, 95% 
CI [0.50-0.98], 
p=0.03 
PROMiSe51 PPMS glatiramer acetate (627) 
placebo (316) 
36 
months 
50.4 14.1% 3-month CDW 
based on 
EDSS 
HR=0.87, 95% 
CI [0.71-1.07], 
p=0.175 
Neuroprotective or repair-promoting strategies 
CUPID63 PPMS 
SPMS 
dronabinol (329) 
placebo (164) 
36 months 52.2 N/A 6-month CDW 
based on 
EDSS, 
change in 
0.1% reduction 
in CDW, 
HR=0.92, 95% 
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MSIS-29 
PHYS 
CI [0.68-1.23], 
p=0.57 
MS-SPI16 PPMS 
SPMS 
biotin (103) 
placebo (51) 
12 months 51.4 N/A Proportion 
with disability 
improvement 
based on 
EDSS and 
T25FW at 9 
months 
confirmed at 
12 months 
12% of 
participants in 
biotin arm 
improved 
compared with 
0 in the placebo 
arm, p=0.005 
 
9HPT = Nine-Hole Peg Test, CDW = confirmed disability worsening, CI = confidence interval, EDSS = Expanded Disability Status 
Scale, HR = hazard ratio, N/A = not applicable, MSIS-29 PHYS = physical impact subscale of the 29-item Multiple Sclerosis Impact 
Scale, OR = odds ratio, PPMS = primary progressive multiple sclerosis, SPMS = secondary progressive multiple sclerosis, T25FW = 
Timed 25-Foot Walk 
 
 Page 31 
Figure legends 
 
Figure 1: Pathogenesis of neurodegeneration in progressive multiple sclerosis 
A large number of potential mechanisms have been hypothesized contribute to tissue injury in 
progressive multiple sclerosis (MS). Focal inflammatory demyelinating lesions are less common 
than in relapsing-remitting MS but do occur in progressive MS.  Acute axonal transection may 
accompany inflammatory demyelination and leads to both antegrade and retrograde axonal 
degeneration. In addition to focal inflammatory lesions, diffusely distributed activated microglia 
are present and elaborate inflammatory mediators and reactive oxygen species (ROS), 
damaging numerous other cellular elements. Chronic demyelination is thought to result in loss 
of the insulating properties of myelin, increased exposure to inflammatory mediators and ROS, 
loss of structural and trophic support, and interruption of saltatory nerve impulse conduction. 
Up-regulation of sodium channel expression and insertion into the demyelinated axonal 
segment may restore function but with increased energy demand from replacement of saltatory 
nerve impulse conduction by continuous conduction. Energy failure and insufficiency of the 
sodium-potassium adenosine triphosphate pump leads to reverse operation of the sodium-
calcium exchanger leads to cytoplasmic calcium accumulation. Calcium overload results in 
activation of calpains, proteases, lipases, and nitric oxide synthase leading to damage to of the 
axonal cytoskeleton and membrane. Dysfunction of axonal mitochondria results from impaired 
mitochondrial transport from the nucleus, oxidative injury, and mutations in mitochondrial DNA 
may lead to impaired energy production and further generation of ROS. Finally release of iron 
from damaged myelin and oligodendrocytes may lead to accumulation of toxic iron species. The 
proposed net result is neurodegeneration due to direct effects of toxic mediators, increased 
cellular energy demand, failure of energy production, and virtual hypoxia.  
 
Figure 2: Categorization of patients with progressive multiple sclerosis 
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Progressive multiple sclerosis is defined by the presence at some time of gradual worsening in 
the absence of (or between) relapses. Clinically, primary progressive and secondary 
progressive multiple sclerosis (MS) are distinguished based on whether there is progression 
from disease onset or whether it follows a relapsing-remitting course, respectively. Patients with 
both forms of progressive MS are further categorized based on the presence or absence clinical 
relapses or new MRI lesions (“active” or “not active”) and of gradual worsening disability 
independent of relapses (“with progression” or “without progression”) in a preceding period of 
time (e.g. one year). An individual patient may move between these categories over time. 
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